HRP20240037T1 - Car t-stanice prema bcma za liječenje multiplog mijeloma - Google Patents

Car t-stanice prema bcma za liječenje multiplog mijeloma Download PDF

Info

Publication number
HRP20240037T1
HRP20240037T1 HRP20240037TT HRP20240037T HRP20240037T1 HR P20240037 T1 HRP20240037 T1 HR P20240037T1 HR P20240037T T HRP20240037T T HR P20240037TT HR P20240037 T HRP20240037 T HR P20240037T HR P20240037 T1 HRP20240037 T1 HR P20240037T1
Authority
HR
Croatia
Prior art keywords
cell
car
seq
domain
treatment
Prior art date
Application number
HRP20240037TT
Other languages
English (en)
Croatian (hr)
Inventor
Beatriz MARTÍN ANTONIO
Álvaro URBANO ISPIZUA
Lorena PÉREZ AMILL
Guillermo SUÑE RODRIGUEZ
Manel JUAN OTERO
Original Assignee
Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)
Hospital Clínic De Barcelona
Universitat De Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Hospital Clínic De Barcelona, Universitat De Barcelona filed Critical Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)
Publication of HRP20240037T1 publication Critical patent/HRP20240037T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
HRP20240037TT 2019-08-02 2020-08-03 Car t-stanice prema bcma za liječenje multiplog mijeloma HRP20240037T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382673 2019-08-02
EP20757544.0A EP4007777B1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma
PCT/EP2020/071831 WO2021023721A1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
HRP20240037T1 true HRP20240037T1 (hr) 2024-03-29

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240037TT HRP20240037T1 (hr) 2019-08-02 2020-08-03 Car t-stanice prema bcma za liječenje multiplog mijeloma

Country Status (18)

Country Link
US (1) US12509525B2 (https=)
EP (2) EP4272837A3 (https=)
JP (1) JP7729561B2 (https=)
AU (1) AU2020325690A1 (https=)
CA (1) CA3148930A1 (https=)
DK (1) DK4007777T5 (https=)
ES (1) ES2971033T3 (https=)
FI (1) FI4007777T3 (https=)
HR (1) HRP20240037T1 (https=)
HU (1) HUE064890T2 (https=)
LT (1) LT4007777T (https=)
PL (1) PL4007777T3 (https=)
PT (1) PT4007777T (https=)
RS (1) RS65094B1 (https=)
SI (1) SI4007777T1 (https=)
SM (1) SMT202400013T1 (https=)
WO (1) WO2021023721A1 (https=)
ZA (1) ZA202201166B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021397A (ko) * 2022-02-09 2025-02-12 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
NO3051026T3 (https=) 2011-10-21 2018-07-28
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Also Published As

Publication number Publication date
US20220267459A1 (en) 2022-08-25
AU2020325690A1 (en) 2022-03-03
ZA202201166B (en) 2022-10-26
DK4007777T5 (da) 2024-08-05
DK4007777T3 (da) 2024-01-15
PL4007777T3 (pl) 2024-03-11
SI4007777T1 (sl) 2024-03-29
JP7729561B2 (ja) 2025-08-26
EP4272837A3 (en) 2024-02-28
FI4007777T3 (fi) 2024-01-11
CA3148930A1 (en) 2021-02-11
US12509525B2 (en) 2025-12-30
SMT202400013T1 (it) 2024-03-13
EP4272837A2 (en) 2023-11-08
EP4007777A1 (en) 2022-06-08
WO2021023721A1 (en) 2021-02-11
HUE064890T2 (hu) 2024-04-28
RS65094B1 (sr) 2024-02-29
JP2022542443A (ja) 2022-10-03
PT4007777T (pt) 2024-01-12
ES2971033T3 (es) 2024-06-03
LT4007777T (lt) 2024-02-12
EP4007777B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7387776B2 (ja) Ｔｉｍ３に対する抗体およびその使用
AU2022202819C1 (en) Antibody-mediated neutralization of Chikungunya virus
Collarini et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients
Guo et al. Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus
HRP20240037T1 (hr) Car t-stanice prema bcma za liječenje multiplog mijeloma
Both et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections
ES2662519T3 (es) Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
AU2025205060A1 (en) Compositions and methods for treating HIV/AIDS with immunotherapy
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US11370830B2 (en) Neutralizing antibodies that bind to the zika virus domain III envelope region
JP2019511212A5 (https=)
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
CN107108721B (zh) 包含hiv-1包膜靶向臂的双特异性分子
BR112019025904A2 (pt) método de fabricação de anticorpos biespecíficos, anticorpos biespecíficos e uso terapêutico de tais anticorpos
HRP20170815T1 (hr) Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2012010714A5 (https=)
RU2015153250A (ru) Cd19-специфический химерный антигенный рецептор и его применения
SI2408476T1 (en) Human immunodeficiency virus (hiv) -neutralizing antibodies
JP2013121353A5 (https=)
IL274160B1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
AU2022358512A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
IL312602A (en) Bcma-targeted car-t cell therapy for multiple myeloma
CN111670195B (zh) 针对流感血凝素的人抗体